A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive. Peptide therapeutics are used to treat metabolic disorders owing to their stability, efficiency, safety as well as tolerability.
This report contains market size and forecasts of Peptide Based Metabolic Disorders Therapeutics in Global, including the following market information:
Global Peptide Based Metabolic Disorders Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Peptide Based Metabolic Disorders Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Exenatide Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Peptide Based Metabolic Disorders Therapeutics include AstraZeneca, Ingro Finanz (Bachem), Eli Lilly, Ipsen, Merck, Novo Nordisk, PolyPeptide Group and Teva Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Peptide Based Metabolic Disorders Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Peptide Based Metabolic Disorders Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Peptide Based Metabolic Disorders Therapeutics Market Segment Percentages, by Type, 2021 (%)
Exenatide
Liraglutide
Others
Global Peptide Based Metabolic Disorders Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Peptide Based Metabolic Disorders Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Peptide Based Metabolic Disorders Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Peptide Based Metabolic Disorders Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Peptide Based Metabolic Disorders Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Peptide Based Metabolic Disorders Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Ingro Finanz (Bachem)
Eli Lilly
Ipsen
Merck
Novo Nordisk
PolyPeptide Group
Teva Pharmaceutical